SEARCH:   Advanced

Blood, 1 July 2006, Vol. 108, No. 1, pp. 382-389. Prepublished online as a Blood First Edition Paper on March 7, 2006; DOI 10.1182/blood-2005-02-0596. This Article Full Text (PDF) All Versions of this Article: 2005-02-0596v1 108/1/382    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Kim, S.-W. Articles by Takaue, Y. Search for Related Content PubMed PubMed Citation Articles by Kim, S.-W. Articles by Takaue, Y. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted March 1, 2005 Accepted December 22, 2005 Myeloablative allogeneic hematopoietic stem cell transplantation for non-Hodgkin lymphoma: a nationwide survey in Japan Sung-Won Kim, Tetsuya E Tanimoto, Noriyuki Hirabayashi, Seiichi Goto, Masahiro Kami, Satoshi Yoshioka, Toshiki Uchida, Kenji Kishi, Yuji Tanaka, Akio Kohno, Masaharu Kasai, Masakazu Higuchi, Masanobu Kasai, Shin-ichiro Mori, Takahiro Fukuda, Koji Izutsu, Hiroshi Sao, Takayuki Ishikawa, Tatsuo Ichinohe, Kengo Takeuchi, Kinuko Tajima, Ryuji Tanosaki, Mine Harada, Shuichi Taniguchi, Kensei Tobinai, Tomomitsu Hotta, and Yoichi Takaue* Hematology and Hematopoietic Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo, Japan Department of Hematology, Tottori University Hospital, Tottori, Japan Department of Internal Medicine, Nagoya Daini Red Cross Hospital, Nagoya, Japan Department of Hematology/Oncology, Kyoto University Hospital, Kyoto, Japan Division of Hematology, Tokai University Hospital, Isehara, Japan Department of Hematology, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan Department of Hematology and Oncology, JA Aichi Showa Hospital, Konan, Japan Department of Internal Medicine, Sapporo Hokuyu Hospital, Sapporo, Japan Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan Department of Cell Therapy and Transplantation Medicine, University of Tokyo, Tokyo, Japan Department of Hematology, Meitetsu Hospital, Nagoya, Japan Department of Pathology, Cancer Institute of Japanese Foundation for Cancer Research, Tokyo, Japan First Department of Internal Medicine (Medicine and Biosystemic Science), Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan Department of Hematology, Toranomon Hospital, Tokyo, Japan * Corresponding author; email: ytakaue{at}ncc.go.jp. We retrospectively surveyed the data of 233 patients who underwent myeloablative allogeneic hematopoietic stem cell transplantation (allo-HSCT) for non-Hodgkin lymphoma (NHL). Donors were HLA-matched relatives in 154 patients (66%) or unrelated volunteers in 60 (26%). Ninety patients (39%) were in complete remission. One hundred ninety-three (83%) received a total body irradiation (TBI)-based regimen, and 40 (17%) received a non-TBI-based regimen. Acute graft-versus-host disease (GVHD) occurred in 155 of the 233 evaluable patients (67%); grade II-IV in 90 (39%) and grade III-IV in 37 (16%). Treatment-related mortality (TRM) was observed in 98 patients (42%), and 68% of them were related to GVHD. In a multivariate analysis, chemoresistance, prior autograft and chronic GVHD were identified as adverse prognostic factors for TRM. Relapse or progression of lymphoma was observed in 21%. The 2-year overall survival rates of the patients with indolent (n = 38), aggressive (n = 111) and lymphoblastic lymphoma (n = 84) were 57%, 42%, and 41%, respectively. In a multivariate analysis, chemoresistance, prior autograft, and prior radiotherapy were identified as adverse prognostic factors for overall survival. Although myeloablative allo-HSCT represents an effective therapeutic option for NHL patients, more work is still needed to decrease TRM and relapse. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: M. Nickelsen, M. Ziepert, S. Zeynalova, B. Glass, B. Metzner, M. Leithaeuser, H. K. Mueller-Hermelink, M. Pfreundschuh, and N. Schmitz High-dose CHOP plus etoposide (MegaCHOEP) in T-cell lymphoma: a comparative analysis of patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) Ann. Onc., December 1, 2009; 20(12): 1977 - 1984. [Abstract] [Full Text] [PDF] N. Schmitz, P. Dreger, B. Glass, and A. Sureda Allogeneic transplantation in lymphoma: current status Haematologica, November 1, 2007; 92(11): 1533 - 1548. [Abstract] [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020